Glaxo’s CEO Search Will Be ‘Relatively Expensive,’ Chairman Says

“The only candidates we would consider are people who are very seriously in the health-care sector,” Hampton told reporters in London. Witty will step down in March, after almost a decade in the top job, following a tumultuous couple of years in which he has faced criticism over the company’s performance. The board is looking both interally and externally for a replacement, Hampton said.
“Nobody starts with a closed mind about internal versus external,” he said. “Normally when you pick an external person, it’s to introduce at least the potential for more change. But with more change is more risk.”